Publications
- Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer2020 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- Modern treatment of non-small cell lung carcinoma2017 | Faculty of Medicine in Pilsen
- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- Current status and prospects of targeted therapies non-small cell lung cancer2016 | Faculty of Medicine in Pilsen
- Nintedanib - interesting alternative forsecond line pulmonaty adenocarcinoma patients2016 | Faculty of Medicine in Pilsen
- Systemic therapy of lung adenocarcinoma2016 | Faculty of Medicine in Pilsen
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Afatinib - non-small cell lung cancer in the second generation targeted therapy2014 | Publication without faculty affiliation
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Third Faculty of Medicine
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Medicine in Pilsen, Faculty of Science, Central Library of Charles University
Loading network view...